BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deykin D, Balko C, Isselbacher KJ. Sugar and Amino Acid Transport by Cells in Culture — Differences between Normal and Malignant Cells. N Engl J Med 1972;286:929-33. [DOI: 10.1056/nejm197204272861707] [Cited by in Crossref: 92] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol 2015;17:434-42. [PMID: 25465392 DOI: 10.1007/s11307-014-0807-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
2 Miyake K, Ogawa D, Okada M, Hatakeyama T, Tamiya T. Usefulness of positron emission tomographic studies for gliomas. Neurol Med Chir (Tokyo) 2016;56:396-408. [PMID: 27250577 DOI: 10.2176/nmc.ra.2015-0305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
3 Gallego GA, Villaamil VM, Grande E, Caínzos IS, Aparicio LM. Crossing paths in Human Renal Cell Carcinoma (hRCC). Int J Mol Sci 2012;13:12710-33. [PMID: 23202921 DOI: 10.3390/ijms131012710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92:874-879. [PMID: 11509120 DOI: 10.1111/j.1349-7006.2001.tb01175.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
5 Christensen M, Kamson DO, Snyder M, Kim H, Robinette NL, Mittal S, Juhász C. Tryptophan PET-defined gross tumor volume offers better coverage of initial progression than standard MRI-based planning in glioblastoma patients. J Radiat Oncol 2014;3:131-8. [PMID: 25414765 DOI: 10.1007/s13566-013-0132-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
6 Nimmagadda S, Ford EC, Wong JW, Pomper MG. Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol 2008;18:136-48. [PMID: 18314068 DOI: 10.1016/j.semradonc.2007.10.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
7 Sun T, Li ZL, Tian H, Wang SC, Cai J. Synthesis and biological evaluation of novel 1-alkyl-tryptophan analogs as potential antitumor agents. Molecules 2009;14:5339-48. [PMID: 20032897 DOI: 10.3390/molecules14125339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Kim OS, Park JW, Lee ES, Yoo RJ, Kim WI, Lee KC, Shim JH, Chung HK. [18F]FET PET is a useful tool for treatment evaluation and prognosis prediction of anti-angiogenic drug in an orthotopic glioblastoma mouse model. Lab Anim Res 2018;34:248-56. [PMID: 30671112 DOI: 10.5625/lar.2018.34.4.248] [Reference Citation Analysis]
9 Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010;2010. [PMID: 20706540 DOI: 10.1155/2010/205357] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 8.5] [Reference Citation Analysis]
10 Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer. Medicine (Baltimore). 2015;94:e1037. [PMID: 26131811 DOI: 10.1097/md.0000000000001037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
11 Nandu H, Wen PY, Huang RY. Imaging in neuro-oncology. Ther Adv Neurol Disord 2018;11:1756286418759865. [PMID: 29511385 DOI: 10.1177/1756286418759865] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
12 Hussein YR, Bandyopadhyay S, Semaan A, Ahmed Q, Albashiti B, Jazaerly T, Nahleh Z, Ali-Fehmi R. Glut-1 Expression Correlates with Basal-like Breast Cancer. Transl Oncol 2011;4:321-7. [PMID: 22190995 DOI: 10.1593/tlo.11256] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
13 Thirabanjasak D, Basturk O, Altinel D, Cheng JD, Adsay NV. Is serous cystadenoma of the pancreas a model of clear-cell-associated angiogenesis and tumorigenesis? Pancreatology 2009;9:182-8. [PMID: 19077470 DOI: 10.1159/000178890] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
14 Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013;15:1058-67. [PMID: 23460322 DOI: 10.1093/neuonc/not002] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 13.3] [Reference Citation Analysis]
15 Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol 2015;6:33. [PMID: 25755649 DOI: 10.3389/fneur.2015.00033] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 17.0] [Reference Citation Analysis]
16 Vellayappan B, Tan CL, Yong C, Khor LK, Koh WY, Yeo TT, Detsky J, Lo S, Sahgal A. Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases. Front Oncol 2018;8:395. [PMID: 30324090 DOI: 10.3389/fonc.2018.00395] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 19.0] [Reference Citation Analysis]
17 Nasr H, Farghaly H, Alqarni A, Al-Salem S, Sayed M. Characteristics of malignant thyroid lesions on [18F] fluorodeoxyglucose (FDG)-Positron emission tomography (PET)/Computed tomography (CT). Eur J Radiol Open 2021;8:100373. [PMID: 34458507 DOI: 10.1016/j.ejro.2021.100373] [Reference Citation Analysis]
18 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
19 Seleit I, Bakry OA, Al-Sharaky DR, Ragab RAA, Al-Shiemy SA. Evaluation of Hypoxia Inducible Factor-1α and Glucose Transporter-1 Expression in Non Melanoma Skin Cancer: An Immunohistochemical Study. J Clin Diagn Res 2017;11:EC09-16. [PMID: 28764171 DOI: 10.7860/JCDR/2017/25077.10022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y, Boyle JO, Kraus DH, Patel S, Shaha AR, Wong RJ, Huryn JM, Shah JP, Singh B. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 2009;9:11. [PMID: 19138406 DOI: 10.1186/1471-2407-9-11] [Cited by in Crossref: 131] [Cited by in F6Publishing: 130] [Article Influence: 10.9] [Reference Citation Analysis]
21 Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247-253. [PMID: 14961197 DOI: 10.1007/s00268-003-7191-5] [Cited by in Crossref: 167] [Cited by in F6Publishing: 154] [Article Influence: 9.8] [Reference Citation Analysis]
22 Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. Cell Metab. 2017;26:49-70. [PMID: 28683294 DOI: 10.1016/j.cmet.2017.06.004] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 39.3] [Reference Citation Analysis]
23 Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG, Soares FA. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011;66:965-72. [PMID: 21808860 DOI: 10.1590/s1807-59322011000600008] [Cited by in Crossref: 115] [Cited by in F6Publishing: 73] [Article Influence: 12.8] [Reference Citation Analysis]
24 la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011;13:806-19. [PMID: 21757446 DOI: 10.1093/neuonc/nor054] [Cited by in Crossref: 180] [Cited by in F6Publishing: 163] [Article Influence: 18.0] [Reference Citation Analysis]
25 Kuang Y, Wang F, Corn DJ, Tian H, Lee Z. In vitro characterization of uptake mechanism of L-[methyl-(3)H]-methionine in hepatocellular carcinoma. Mol Imaging Biol 2014;16:459-68. [PMID: 24488484 DOI: 10.1007/s11307-014-0720-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Cooper R, Sarioğlu S, Sökmen S, Füzün M, Küpelioğlu A, Valentine H, Görken IB, Airley R, West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 2003;89:870-6. [PMID: 12942120 DOI: 10.1038/sj.bjc.6601202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
27 Ellingson BM, Bendszus M, Sorensen AG, Pope WB. Emerging techniques and technologies in brain tumor imaging. Neuro Oncol 2014;16 Suppl 7:vii12-23. [PMID: 25313234 DOI: 10.1093/neuonc/nou221] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
28 Sipos D, László Z, Tóth Z, Kovács P, Tollár J, Gulybán A, Lakosi F, Repa I, Kovács A. Additional Value of 18F-FDOPA Amino Acid Analog Radiotracer to Irradiation Planning Process of Patients With Glioblastoma Multiforme. Front Oncol 2021;11:699360. [PMID: 34295825 DOI: 10.3389/fonc.2021.699360] [Reference Citation Analysis]
29 Ertl-Wagner B, Ingrisch M, Niyazi M, Schnell O, Jansen N, Förster S, la Fougère C. [PET-MR in patients with glioblastoma multiforme]. Radiologe 2013;53:682-90. [PMID: 23949437 DOI: 10.1007/s00117-013-2500-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M. Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal. 2020;18:83. [PMID: 32493394 DOI: 10.1186/s12964-020-00586-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
31 Kurata T, Oguri T, Isobe T, Ishioka S, Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn J Cancer Res. 1999;90:1238-1243. [PMID: 10622535 DOI: 10.1111/j.1349-7006.1999.tb00702.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 2.9] [Reference Citation Analysis]
32 Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev. 2016;8:5-9. [PMID: 28510148 DOI: 10.1007/s12551-015-0186-2] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 20.4] [Reference Citation Analysis]
33 Pretze M, Wängler C, Wängler B. 6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses. Biomed Res Int 2014;2014:674063. [PMID: 24987698 DOI: 10.1155/2014/674063] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]